Blood pressure synthesis inhibitors

Logically, ADH receptor antagonists, and ADH synthesis and release inhibitors can be effective aquaretics. ADH, 8-arginine vasopressin [113-79-17, is synthesized in the hypothalamus of the brain, and is transported through the supraopticohypophyseal tract to the posterior pituitary where it is stored. Upon sensing an increase of plasma osmolaUty by brain osmoreceptors or a decrease of blood volume or blood pressure detected by the baroreceptors and volume receptors, ADH is released into the blood circulation it activates vasopressin receptors in blood vessels to raise blood pressure, and vasopressin V2 receptors of the nephrons of the kidney to retain water and electrolytes to expand the blood volume. 

Atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), and C-type natriuretic peptide (CNP) are members of a family of so-called natriuretic peptides, synthesized predominantly in the cardiac atrium, ventricle, and vascular endothelial cells, respectively (G13, Y2). ANP is a 28-amino-acid polypeptide hormone released into the circulation in response to atrial stretch (L3). ANP acts (Fig. 8) on the kidney to increase sodium excretion and glomerular filtration rate (GFR), to antagonize renal vasoconstriction, and to inhibit renin secretion (Ml). In the cardiovascular system, ANP antagonizes vasoconstriction and shifts fluid from the intravascular to the interstitial compartment (G14). In the adrenal cortex, ANP is a powerful inhibitor of aldosterone synthesis (E6, N3). At the hypothalamic level, ANP inhibits vasopressin secretion (S3). It has been shown that some of the effects of ANP are mediated via a newly discovered hormone, called adreno-medullin, controlling fluid and electrolyte homeostasis (S8). The diuretic and blood pressure-lowering effect of ANP may be partially due to adrenomedullin (V5). 

L A. By blocking renal prostaglandin synthesis, COX-2 inhibitors, such as rofecoxib, decrease the blood flow to the juxtaglomerular apparatus, thus stimulating the release of renin and subsequent Na" retention and blood pressure elevation. Rofecoxib is neither metabolized nor induced by CYP2C9. It decreases rather than increases renal blood flow and does not increase the excretion of hydrochlorothiazide. Item D is incorrect because rofecoxib has very little effect on COX-1 and prostaglandins are not a major controlling factor of peripheral vascular tone. Rofecoxib does not decrease basal metabolic rate. 

Another important acid derived from the corresponding unsamrated acid family is the a-alkyl substituted acid (C). This compound is used in the synthesis of Aliskiren (the active ingredient of Tektuma ) which Novartis has recently been granted FDA approval as the first-in-class renin inhibitor for control of blood pressure. It is estimated that large volumes of this intermediate will be required in the future but the best ee reported so far for production of this intermediate is 95 % as shown in Figure 1.8. ... 

We have recently analysed the effects of an oral dose of quercetin, the most abundant dietary flavonoid, on the hypertension, oxidant status and renal, cardiac and vascular alterations induced in rats by chronic inhibition of NO synthesis with N-nitro L-arginine methylester (L-NAME). Administration of this NO synthase inhibitor to rats for six weeks induced a progressive increase in systolic blood pressure, but concomitant administration of an oral daily dose of quercetin (10 mg Kg 1) inhibited the development of hypertension induced by L-NAME (Duarte et al, 1999, Meth. Find. Exp. Clin. Pharmacol. 21 (suppl. A), 40). Moreover, when... 

ACE inhibitors prevent the formation of angiotensin II by angiotensin-converting enzyme (ACE) and thereby reduce peripheral vascular resistance and blood pressure. In addition, ACE inhibitors prevent the effect of angiotensin II on protein synthesis in myocardial and vascular muscle cells, and thus diminish ventricular hypertrophy. As adverse effects, ACE inhibitors may provoke dry cough, impaired renal function, and hyperkalemia. When ACE inhibitors are poorly tolerated, an ATq-receptor antagonist can be given. 

It was observed that rats with a transient MCA occlusion have a larger brain infarction when recombinant human IL-1 P is injected into the lateral ventricle immediately after reperfusion [7,41]. Similar results have been obtained in rats with a permanent MCA occlusion [7,42]. The intraventricular injection of recombinant human IL-1 p also enhances the formation of brain edema and increases both the number of neutrophils in ischemic areas and neutrophil-endothelial cell adhesion. The most widely recognized functions of IL-1 appear to be the induction of endothelial cell adhesion molecule expression and the promotion of neutrophil tissue infiltration [7,41]. These observations suggest that IL-1 may play a deleterious role in cerebral ischemia. Studies showing a reduction in infarct size after the administration of IL-1 antagonists or inhibitors provide further evidence of the importance of IL-1 in cerebral ischemia [41,43-49]. The possible harmful mechanisms induced or activated by IL-1 include fever, increased heart rate and arterial blood pressure, enhancement of N-methyl-D-aspartate-mediated injury, proliferation of microglia, release of arachidonic acid, and stimulation of NO synthesis [7,50]. 

Losartan blocks the vascular constrictor effect of Ang II, the Ang Il-induced aldosterone synthesis and/or release, and the All-induced cardiovascular growth. In various models of experimental hypertension, losartan prevents or reverses the elevated blood pressure and the associated cardiovascular hypertrophy similar to angiotensin converting enzyme (ACE) inhibitors. Subsequently con-tolled clinical trials revealed that losartan is a new and valuable drug for treatment of hyper-... 

---